Boston, MA -- (SBWIRE) -- 11/23/2015 -- Pompe disease, a type of LSD, is caused by mutations in the GAA gene. These mutations inhibit the mechanism of action of GAA, an enzyme responsible for catabolizing glycogen, resulting in accumulation of glycogen in the lysosomes of the cells. The buildup of glycogen in certain organs and tissues, especially in the muscles, hinders the normal functions of the organs. Pompe disease can be further classified as infantile-onset and adult-onset Pompe disease. As the disease is an autosomal recessive hereditary disorder, both parents are carriers and can pass one copy of the mutated gene to their offspring. The disease affects both men and women.

Get More Details on this Report and a Full Table of Contents at Pompe Disease Market in the US 2015-2019

Technavio's analysts forecast the pompe disease market in the US to grow at a CAGR of 10.68 % over the period 2014-2019.

Covered in this report
This report covers the present scenario and the growth prospects of the pompe disease market in US for the period 2015-2019. To calculate the market size, the report considers revenue from the sales of the drugs available in the US market and the drug candidates that are in various phases of development for the treatment of Pompe disease.

The report also presents the vendor landscape and a corresponding detailed analysis of the major vendors in the market. In addition, it discusses the major drivers that influence the growth and the challenges faced by the vendors and the market at large, as well as the key trends that contribute to the growth the market.

Technavio's report, Pompe Disease Market in the US 2015-2019, has been prepared based on an in-depth market analysis with inputs from industry experts. It also covers the landscape of the market in the US and its growth prospects in the coming years. The report includes a discussion of the key vendors operating in this market.

Key vendors

-Amicus Therapeutics
-BioMarin Pharmaceutical
-Genzyme

Other prominent vendors

-Audentes Therapeutics
-EpiVax
-Oxyrane
-Sangamo BioSciences
-Valerion Therapeutics

Market driver

-Special provision for orphan drugs
-For a full, detailed list, view our report

Market challenge

-Limited patient population
-For a full, detailed list, view our report

Market trend

-Growing public awareness
-For a full, detailed list, view our report

Key questions answered in this report

-What will the market size be in 2019 and what will the growth rate be?
-What are the key market trends?
-What is driving this market?
-What are the challenges to market growth?
-Who are the key vendors in this market space?
-What are the market opportunities and threats faced by the key vendors?
-What are the strengths and weaknesses of the key vendors?

Companies Mentioned in this Report: Amicus Therapeutics, BioMarin Pharmaceutical, Genzyme, Audentes Therapeutics, EpiVax, Oxyrane, Sangamo BioSciences, Valerion Therapeutics.

About Fast Market Research
Fast Market Research is a leading distributor of market research and business information. Representing the world's top research publishers and analysts, we provide quick and easy access to the best competitive intelligence available. Our unbiased, expert staff is always available to help you find the right research to fit your requirements and your budget. For more information about these or related research reports, please visit our website at http://www.fastmr.com or call us at 1.800.844.8156.

Browse all Pharmaceuticals research reports at Fast Market Research

You may also be interested in these related reports:

-Pompe Disease Global Clinical Trials Review, H1, 2015
-Global Pompe Disease Market 2015-2019
-Global Inflammatory Bowel Disease Market 2015-2019
-The National Institute of Diabetes and Digestive and Kidney Diseases - Pharmaceuticals & Healthcare - Deals and Alliances Profile
-Frontier Pharma: Alzheimer's Disease - Identifying and Commercializing First-in-Class Innovation